Frontlight ResearchEarly access
What researchers published on Myeloproliferative neoplasms
3,019 papers, newest first.
Showing 60 of 3,019
CAR-T Targeting of Mutant Calreticulin Selectively Eradicates Myeloproliferative Neoplasm-Sustaining Stem Cells.Blood
How I diagnose myeloid or lymphoid neoplasms with tyrosine kinase gene fusions.American journal of clinical pathology
Low dose pre-transplant splenic radiotherapy for myeloproliferative neoplasms.Leukemia & lymphoma
Transfusion-related cost and time burden offsets associated with pacritinib versus best available therapy in patients with myelofibrosis: an economic evaluation based on the PERSIST-2 trial.Future oncology (London, England)
The new Iron Age in polycythemia vera.Blood
Case reportThrombocytapheresis for Extreme Thrombocytosis: A 20-Year Single-Center Experience With Acute and Chronic Use in Myeloproliferative Neoplasms.Journal of clinical apheresis
Case reportCase Report: Real-world experience with pacritinib after prior ruxolitinib exposure in myelofibrosis in Saudi Arabia: a report of five cases.Frontiers in medicine
Hematological trajectories and pregnancy complications in essential thrombocythemia and polycythemia vera.Annals of hematology
Effects of calreticulin mutations on HLA class I expression in myeloproliferative neoplasms.JCI insight
Portal and hepatic vein thrombosis in Philadelphia-negative myeloproliferative neoplasms: Insights from the National Inpatient Sample.Thrombosis research
ReviewSGLT2 Inhibitors and Hemoglobin Improvement in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Mechanistic Rationale and Emerging Clinical Evidence.Anemia
ReviewArterial thrombosis redirects the natural history of myeloproliferative neoplasms: A biological perspective.Annals of hematology
Association does not establish causation. Comment on: "Overuse of thrombopoietin receptor agonists driven by suboptimal response is associated with myelofibrosis in pediatric immune thrombocytopenia".Haematologica
Case report[Coronary Artery Bypass Grafting for Coronary Arteritis Induced by Myeloproliferative Neoplasms:Report of a Case].Kyobu geka. The Japanese journal of thoracic surgery
ReviewMomelotinib for the treatment of myelofibrosis in patients with moderate-to-severe anemia: a drug safety evaluation.Expert opinion on drug safety
Review[Clinical presentation, diagnosis, prognosis, and risk-adapted treatment of chronic BCR::ABL1-negative myeloproliferative neoplasms].Innere Medizin (Heidelberg, Germany)
High prevalence and immunophenotypic diversity of clonal T‑large granular lymphocytes in JAK2‑mutated myeloproliferative neoplasms.Annals of hematology
Case reportIsolated add(12)(p13) in a BCR::ABL1-Negative Neutrophilic Myeloproliferative Neoplasm Lacking Canonical Driver Mutations: A Case Report.Cureus
QRISK3 Assessment Identified Essential Thrombocythemia Patients at High Risk of Thrombotic Events Regardless of Revised IPSET-T Score and JAK2 Mutational Status.EJHaem
ReviewAdvances in Myeloproliferative Neoplasms by single-cell omics studies.Experimental hematology
ReviewRusfertide for the treatment of polycythemia vera.Expert opinion on pharmacotherapy
ReviewRopeginterferon alfa-2b for adults with polycythemia vera: an updated perspective from approval to real-world clinical treatment.Expert review of hematology
Systemic inflammation response index and total cholesterol in relation to the occurrence of major adverse cardiovascular and cerebrovascular events in patients with myeloproliferative neoplasms.BMC cardiovascular disorders
Clinical risk features and genetic findings in essential thrombocythemia and polycythemia vera of childhood and adolescence: prospective insights from the German MPN Childhood Registry.Haematologica
Case reportSubclonal AGGF1::PDGFRB rearrangement in a myelodysplastic/myeloproliferative neoplasm with suboptimal response to imatinib.American journal of clinical pathology
Case reportMasked Triple-Negative Polycythemia Vera Initially Presenting as Iron Deficiency and Pernicious Anemia.Cureus
Case reportNTRK1-Rearranged Cutaneous Non-Langerhans Cell Histiocytosis With Durable Response to TRK Inhibitor in a Patient With Primary Myelofibrosis.Journal of cutaneous pathology
ReviewTLR2 Signaling in Myeloproliferative Neoplasms: Pathophysiological Roles, Mutation-Dependent Heterogeneity, and the Differential Efficacy of Ruxolitinib.International journal of molecular sciences
ReviewMeasurable Residual Disease (MRD) Monitoring in Myeloproliferative Neoplasms.Cancers
Real-world treatment patterns, outcomes, and healthcare resource use for myelofibrosis in Brazil: Subgroup analysis of the METER study.Hematology, transfusion and cell therapy
Bone Marrow Cell Depletion in Myelofibrosis Is Associated With High-Risk Features and Shortened Survival: A Bone Marrow Pathology Group Study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Case reportTropheryma whipplei Pneumonia with Myelofibrosis: A Rare Actinomycetia Case Report and Literature Review.Infection and drug resistance
Evaluating the Fiscal Burden of Essential Thrombocythemia in Sweden Through Application of a Government Perspective.ClinicoEconomics and outcomes research : CEOR
Case reportRetroperitoneal Hematoma in Essential Thrombocythaemia: A Diagnostic Challenge.La Clinica terapeutica
ReviewHow could calreticulin-targeting therapies change the myelofibrosis transplant paradigm?Bone marrow transplantation
Randomised trialFirstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.Blood cancer journal
In plain wordsRead moreRead the paper on PubMedReviewNew Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.American journal of hematology
High Initial Dose and Accelerated vs. Slow Titration Ropeginterferon Alfa-2b for Polycythemia Vera: A Meta-Analysis.Blood advances
Observational studyLong-term hydroxyurea therapy alters bone marrow megakaryocyte morphology and associates with prognosis in myeloproliferative neoplasms.Annals of hematology
ReviewCalreticulin and myeloproliferative neoplasms: linking biology to targeted therapies.Expert review of clinical immunology
Predicting long-term survival in primary myelofibrosis.Leukemia
ReviewCardiac diagnostic modalities in polycythemia vera: A narrative review.The Journal of international medical research
Incidence of thrombosis and bleeding in patients with JAK2-positive myeloproliferative neoplasms receiving low-dose aspirin: a systematic review and meta-analysis.Journal of thrombosis and haemostasis : JTH
Rusfertide for Polycythemia Vera: Incremental Benefit Assessment.American journal of hematology
Case reportBiopsy-Proven Hepatic Extramedullary Hematopoiesis With Chronic Portal Vein Thrombosis in JAK2 V617F-Positive Prefibrotic Myelofibrosis: Contributors to Noncirrhotic Portal Hypertension.ACG case reports journal
Polycythemia Vera Transforming to Pure Erythroid Leukemia: A Diagnostic Mimic of Thrombotic Microangiopathy With High-Risk TP53 Biology.Case reports in hematology
Proteomic profiling of high purity extracellular vesicle subtypes from megakaryoblastic leukemia cells provides insights into myeloproliferative neoplasm biology.Extracellular vesicles and circulating nucleic acids
High-normal and mildly elevated bilirubin levels in prefibrotic primary myelofibrosis patients are associated with lower thrombotic risk.Scandinavian journal of clinical and laboratory investigation
Beyond Phlebotomy: Iron Homeostasis in the Next Phase of Polycythemia Vera Management.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Review"Beyond the Genetic Blueprint: Disrupting the Epitranscriptomic Code in Myeloproliferative Neoplasms".Experimental hematology
The Hyperviscous Heart: Reversible Cardiomyopathy in Polycythemia Vera.European heart journal. Cardiovascular Imaging
Case reportCombined central retinal and posterior ciliary artery occlusion in a young female with primary myelofibrosis and Sweet's syndrome: A case report.Taiwan journal of ophthalmology
Myelofibrosis end points and self-evident truths.Blood
Inflammasome, clonal stability and the thrombotic circuit in myeloproliferative neoplasms: an antecedent framework.Clinical and experimental medicine
Clinical Characteristics of Coexistent Chronic Myeloid Leukemia and BCR::ABL1 Negative Myeloproliferative Neoplasms: A Retrospective Study.Hematological oncology
American Society of Hematology 2026 Guidelines for the Management of Myelofibrosis in Adults.Blood advances
GuidelinePractical Management of Cytopenias in Patients with Myelofibrosis Adapted to the Portuguese Reality.Acta medica portuguesa
In plain wordsRead moreRead the paper on PubMedFDX1 is associated with CALR abundance and JAK-STAT-related inflammatory signaling in myeloproliferative neoplasms.Frontiers in oncology
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Molecular Consequences and Targeting of PPM1D Overexpression in Myeloproliferative Neoplasms.Blood